Manufactures pharmaceutical products, with FY26 revenue of Rs 641.29 crore. Operations are centred at a manufacturing site in Derabassi, Punjab, where a centralised warehouse with 11,000-pallet capacity is being built under an MOU worth about Rs 40 crore, adjoining the existing Global Business Unit. Overseas reach is supported through a Dubai subsidiary, identified as a recipient of fresh investment. The cost structure is materials-heavy, with raw materials at 42.4% of revenue and employees at 21.5%; other operating expenses add 27.4% and depreciation 4.8%. A Rs 137.20 crore preferential warrant issue to a promoter group entity is being put to shareholders, with Rs 53 crore earmarked for working capital, Rs 41.40 crore for further manufacturing and warehouse expansion, Rs 5 crore for the Dubai subsidiary, Rs 2 crore for R&D and Rs 1.5 crore for a technology upgrade. An earlier Rs 255.61 crore preferential warrant issue was deployed across business expansion, subsidiary investments, working capital and general corporate purposes. AR · MarketPing reader · 2026-08-02
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,039 | 1,207 | 1,281 | 562 | 641 |
| EBITDA (ex other income) | 196 | 203 | 641 | 204 | 34 |
| margin % | 18.9 | 16.8 | 50.0 | 36.3 | 5.3 |
| Owners' profit | (2) | 0 | 0 | 0 | 0 |
| EPS, as reported (₹) | (0.36) | 8.06 | 71.24 | 37.25 | 4.95 |
| ROE % · ROCE % | (0.4) · 7.4 | 7.0 · 12.3 | 45.2 · 67.1 | 21.4 · 21.4 | 3.0 · 3.6 |
| Debt / equity (x) | 1.59 | 1.26 | 0.02 | 0.03 | 0.01 |
| Cash from operations | 150 | 195 | (181) | (25) | (63) |
| Capex | (18) | (13) | (45) | (64) | (88) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12 | 9 | 138 | 153 | 153 | 151 | 170 | 191 |
| Profit before tax | 1 | (1) | 230 | 10 | 10 | 16 | 12 | 33 |
| Net profit | 0 | 0 | 222 | 9 | 8 | 10 | 15 | 25 |
| EPS (₹) | 0.07 | 0.00 | 32.96 | 1.28 | 1.00 | 1.17 | 1.81 | 2.84 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 6 Sept 2026 · Newspaper publication of 31st AGM notice and e-voting details | compliance | minimal | — | — |
| 6 Sept 2026 · Newspaper publication for 31st AGM notice and e-voting details | compliance | minimal | — | — |
| 5 Sept 2026 · Ind-Swift Labs files Annual Report for FY 2025-26; AGM on September 30 | compliance | minimal | — | — |
| 5 Sept 2026 · Ind-Swift Labs 31st AGM on September 30, 2026 via video conferencing | board shareholder meetings | low | — | — |
| 4 Sept 2026 · 31st AGM on 30 Sept 2026 via video conferencing, newspaper notice filed | compliance | minimal | — | — |
| 4 Sept 2026 · Preferential warrant issue price set at Rs 196 each | fund raising | high | — | — |
| 2 Sept 2026 · Board meeting outcome: New independent director appointed, AGM set for Sept 30 | management changes | medium | — | — |
| 28 Aug 2026 · NSE seeks clarification on volume spurt; company says unaware of reason | regulatory legal | medium | — | — |
| 27 Aug 2026 · BSE query on volume spike; firm says no undisclosed info | regulatory legal | medium | — | — |
| 27 Aug 2026 · BSE seeks clarification from Ind-Swift on unusual volume movement | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 57.0 | 28.9 | 135 of 169 | 20% |
| P/B | 2.4 | 3.3 | 63 of 163 | 62% |
| ROCE | 3.5 | 10.8 | 138 of 183 | 25% |
| ROE | 3.0 | 10.4 | 133 of 171 | 22% |
| Debt / Equity | 0.0 | 0.1 | 52 of 171 | 70% |
| EBITDA margin | 21.3 | 17.5 | 69 of 165 | 59% |
| Revenue growth | 25.4 | 16.3 | 58 of 161 | 64% |
| Profit growth | 181.3 | 30.9 | 26 of 158 | 84% |
| Market cap | 3383 | 839 | 68 of 182 | 63% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
